PIK3CA and neoplasm: Moreover, ctDNA analysis can identify tumor alterations that may help in treatment choice, both as predictor of response mutations (e.g., PIK3CA mutations for PIK3CA-inhibitors) and resistance (e.g., ESR1 mutations).